• Clinical Trials

    __00.png Call: 1-877-547-1750

            Email: CancerClinicalTrials@bassett.org

     

    Clinical trials are the final step in a long process that often begins in the lab. Many cancer treatments used today are results of past clinical trials. Clinical trials are key to developing new methods to prevent, detect, and treat cancer. It is through clinical trials that researchers can determine whether new treatments are safe and effective and work better than current treatments. When you take part in a clinical trial, you add to our knowledge about cancer and help improve cancer care. For more information about clinical trials, click this link provided by the National Cancer Institute.

    The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).

    ACT (About Clinical Trials) is a website to help empower people to understand cancer clinical trials and discuss this option with their doctors and loved ones. This unique resource features unscripted interviews with clinical trial participants, doctors, patient rights advocates, and others. Their honest stories and the information on this site will help you ACT toward having informed discussions with those committed to your care.

    For more information regarding ACT, please follow this link and explore.

    Learn more about Bassett's Cancer Clinical Trials program by clicking here, where patients tell their stories.

    Blood Cancer

    Connect® MDS/AML Disease Registry

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT01688011

    (Project 1246938) 
    Eric Bravin, M.D. 

    Breast Cancer

    A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02750826

    (Project 1246873) 
    Eric Bravin, M.D.

     

    A011502: A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02927249

    (Project 1246871) 
    Eric Bravin, M.D.

     

    A221505: RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03414970

    (Project 1494080) 
    Julia Manzerova, M.D.

     

    NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT01872975

    (Project 1246932)
    Timothy Korytko, M.D.

     

    NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02488967

    (Project 1246890) 
    Anush Patel, M.D.

     

    S1703: A Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Markers Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03723928

    (Project 1350363) 
    Eric Bravin, M.D.

    Colon Cancer

    A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02912559

    (Project 1246881)
    Eric Bravin, M.D. 

    Kidney Cancer

    A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03793166

    (Project 1442850)
    Eric Bravin, M.D. 

    Lung Cancer

    LUNGMAP
    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03851445
    (Project 1368750)
    Eric Bravin, M.D.

                                                                                                                                       

    S1800A
    A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03971474
    (Project 1447130)
    Eric Bravin, M.D.

                                                                                                                                       

    S1900A
    A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03845296 
    (Project 1389376)
    Eric Bravin, M.D.

                                                                                                                                                                                                                

    A151216
    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02194738
    (Project 1246946)
    Eric Bravin, M.D.

    ____________________________________________________________________________________________

    E4512
    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02201992
    (Project 1246948)
    Eric Bravin, M.D.

    ____________________________________________________________________________________________

    A081105
    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02193282
    (Project 1246947)
    Eric Bravin, M.D.
    ____________________________________________________________________________________________

    EA5142
    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02595944
    (Project 1246981)
    Eric Bravin, M.D.

    Melanoma

    EA6134: A Randomized Phase III Trial of Dabrafenib +  Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02224781

    (Project 1246965)
    Eric Bravin, M.D.

     

    EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (Temporarily closed to accrual)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02339571

    (Project 1246966)
    Eric Bravin, M.D.

     

    S1801: RA Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT03698019

    (Project 1246966)
    Eric Bravin, M.D.

    Prostate Cancer

    NRG-GU005: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03367702

    (Project 1363197) 
    Timothy Korytko, M.D.

     

    NRG-GU006: A Phase II Double Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamode in Recurrent Prostate Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT03371719

    (Project 1297423) 
    Timothy Korytko, M.D.